Topiroxostat
A xanthine oxidase inhibitor used in the treatment of gout
Topiroxostat is a xanthine oxidase inhibitor used primarily in the management of gout and hyperuricemia. It is a non-purine selective inhibitor that reduces the production of uric acid by inhibiting the activity of xanthine oxidase, an enzyme involved in the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Mechanism of Action
Topiroxostat works by selectively inhibiting the enzyme xanthine oxidase. This enzyme is responsible for the oxidation of hypoxanthine to xanthine and xanthine to uric acid, which is the final step in the catabolism of purines in humans. By inhibiting this enzyme, topiroxostat effectively reduces the production of uric acid, thereby lowering serum uric acid levels and preventing the formation of uric acid crystals in joints and tissues.
Clinical Use
Topiroxostat is indicated for the treatment of hyperuricemia in patients with gout. It is particularly useful in patients who are intolerant to other xanthine oxidase inhibitors such as allopurinol. The drug is administered orally and is typically well-tolerated by patients.
Side Effects
Common side effects of topiroxostat include nausea, diarrhea, and headache. Some patients may experience liver function test abnormalities, and it is recommended to monitor liver function during treatment. Rarely, hypersensitivity reactions may occur.
Pharmacokinetics
Topiroxostat is absorbed orally and undergoes hepatic metabolism. It is excreted primarily in the urine. The drug has a half-life that allows for convenient dosing schedules, typically once or twice daily.
Development and Approval
Topiroxostat was developed as an alternative to existing treatments for hyperuricemia and gout, with a focus on providing a selective inhibition of xanthine oxidase. It has been approved for use in several countries and continues to be studied for its efficacy and safety in various populations.
Related pages
Ad. Transform your life with W8MD's Budget GLP-1 injections from $29.99
W8MD offers medical weight loss programs including NYC medical weight loss and Philadelphia medical weight loss offering:
- Affordable GLP1 shots (generic and brand names) such as
- Wegovy NYC (Semaglutide)
- Zepbound NYC /
- Learn more: Budget GLP1 weight loss injections NYC & Philadelphia GLP1 weight loss shots
- Most insurances accepted
- Lowest cost GLP1 weight loss NYC such as Semaglutide starting from $29.99/week and $45.00/week (Tirzepatide) with insurance.
- Prescription weight loss NYC including:
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your physician weight loss journey today at our:
- NYC medical weight loss
- Philadelphia medical weight loss
- Call 718-946-5500 for NYC or 215-676-2334 for Philadelphia
- Tags:
Budget glp1 weight loss NYC,
Zepbound NYC,
Philadelphia medical weight loss,
Wegovy NYC,
Zepbound Philadelphia,
Budget GLP1 shots Philadelphia
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
